We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Withdraws Appeal on Orphan Drug Exclusivity for Gralise
FDA Withdraws Appeal on Orphan Drug Exclusivity for Gralise
A federal court decision this fall granting orphan drug marketing exclusivity to Depomed’s post-shingles pain drug Gralise will stand, after the FDA withdrew an appeal filed earlier this month.